E-LIB Suche - Ergebnisse für: Brima Musa Younis

1

Leishmania donovani-Induced Immune Dysregulation among Suda..:

Elsammani, E.E.M. ; Musa, Brima Younis ; Elfaki, Mona Elfaki Eltahir..
Advances in Infectious Diseases. 10 (2020) 5 - p. 235-242 , 2020

Link: https://doi.org/10.4236/..

2

Differences in the Cellular Immune Response during and afte..:

Torres, Ana ; Younis, Brima Musa ; Alamin, Mohammed...
Journal of Epidemiology and Global Health. , 2024

Link: https://doi.org/10.1007/..

3

Safety and efficacy of paromomycin/miltefosine/liposomal am..:

Younis, Brima Musa ; Mudawi Musa, Ahmed ; Monnerat, Séverine...
PLOS Neglected Tropical Diseases. 17 (2023) 11 - p. e0011780 , 2023

Link: https://doi.org/10.1371/..

4

Paromomycin and Miltefosine Combination as an Alternative t..:

Musa, Ahmed M ; Mbui, Jane ; Mohammed, Rezika...
Clinical Infectious Diseases. 76 (2022) 3 - p. e1177-e1185 , 2022

Link: https://doi.org/10.1093/..

5

Prevalence of Latent Tuberculosis Infection (LTBI) among Ho..:

Osman, Saima Abdalrhman ; Saeed, Walla Saeed Eltahir ; Musa, Ahmed Mudawi...
Journal of Tuberculosis Research. 5 (2017) 1 - p. 69-76 , 2017

Link: https://doi.org/10.4236/..

6

Safety and efficacy of paromomycin/miltefosine/liposomal am..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0011780&type=printable. , 2023

Link: https://doi.org/10.1371/..

7

PKDL lesion distribution grade over time by treatment arm–m..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.g003. , 2023

Link: https://doi.org/10.1371/..

8

Supplementary material:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.s001. , 2023

Link: https://doi.org/10.1371/..

9

CONSORT 2010 checklist of information to include when repor..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.s003. , 2023

Link: https://doi.org/10.1371/..

10

Baseline characteristics by treatment arm and overall–ITT s..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.t001. , 2023

Link: https://doi.org/10.1371/..

11

Summary of treatment emergent adverse events–mITT set:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.t003. , 2023

Link: https://doi.org/10.1371/..

12

Kaplan-Meier curve of time to complete cure by treatment ar..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.g002. , 2023

Link: https://doi.org/10.1371/..

13

Fig 1 -:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.g001. , 2023

Link: https://doi.org/10.1371/..

14

Median plasma and skin concentrations of miltefosine on day..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.g004. , 2023

Link: https://doi.org/10.1371/..

15

Primary efficacy outcome of definitive cure at 12 months by..:

Brima Musa Younis ; Ahmed Mudawi Musa ; Séverine Monnerat...
doi:10.1371/journal.pntd.0011780.t002. , 2023

Link: https://doi.org/10.1371/..